Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757330 | 0.92 | CA4 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10456836 | 0.92 | CA4 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL144129 | 0.90 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| Fluoride Ion SCHEMBL245850 | 0.87 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| Iodide SCHEMBL10788331 | 0.87 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| Bromide SCHEMBL8745388 | 0.87 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL4175940 | 0.87 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6545093 | 0.82 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| Bromide SCHEMBL10826980 | 0.81 | ESR2 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13401281 | 0.81 | ACHE (0.71) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5334699-A | Polymeric initiator compounds | XEROX CORPORATION (US) | 1994-08-02 | — | — | US | claimed |
| US-10421727-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2019-09-24 | — | — | US | disclosed |
| US-20170369447-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-12-28 | — | — | US | disclosed |
| US-9840471-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150376136-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-6326398-B1 | Oxamic acids and derivatives as thyroid receptor ligands | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| EP-1157001-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2000051971-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| US-5654468-A | ANTILIPID, ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | disclosed |
| US-5334699-A | Polymeric initiator compounds | XEROX CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421727-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPA1 | CA1 387/4885CA2 155/4885CA7 543/4885 |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | CA1 1663/4885CA2 1011/4885CA7 1048/4885 |
| US-20150376136-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPA1 | CA1 387/4885CA2 155/4885CA7 543/4885 |
| US-20170369447-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPA1 | CA1 387/4885CA2 155/4885CA7 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.